Antidepressant
Legal status |
---|
Legal status | - AU: S4 (Prescription only)
- BR: Class C1 (Other controlled substances)[1]
|
---|
Identifiers |
---|
|
CAS Number | - 51-12-7 Y
|
---|
PubChem CID | |
---|
DrugBank | - DB04820 Y
|
---|
ChemSpider | - 4317 Y
|
---|
UNII | |
---|
KEGG | - D07337 Y
|
---|
ChEBI | |
---|
ChEMBL | |
---|
CompTox Dashboard (EPA) | - DTXSID1023362
|
---|
ECHA InfoCard | 100.000.073 |
---|
Chemical and physical data |
---|
Formula | C16H18N4O2 |
---|
Molar mass | 298.346 g·mol−1 |
---|
3D model (JSmol) | |
---|
|
InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22) YKey:NOIIUHRQUVNIDD-UHFFFAOYSA-N Y |
(verify) |
Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.[2] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.[3][4]
Side effects include agitation and insomnia, less frequently dry mouth, dizziness, blurred vision, and hypomania, and rarely leukopenia and hepatitis. As with other MAOIs, a hypertensive crisis can be triggered by co-ingestion of tyramine. It is metabolized into isoniazid, an anti-tuberculosis agent, and so is contraindicated in patients with tuberculosis. The recommended dosage range is 75 to 200 mg per day, with maintenance doses as low as 12.5 mg every other day.[5]
The antiatherogenic activity of nialamide was used to design pyridinolcarbamate.[6]
See also
- Hydrazine (antidepressant)
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
- ^ Gad SC (26 April 2012). Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. pp. 138–. ISBN 978-1-4398-4567-7.
- ^ Shorter E (28 September 2008). Before Prozac: The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5.
- ^ Council on Drugs (1971). AMA Drug Evaluations (Report). Chicago: American Medical Association. LCCN 75147249. Retrieved April 5, 2021.
- ^ Bencze WL, Hess R, DeStevens G (6 December 2012). "Hypolipidemic Agents". Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Vol. 13. Springer Science & Business Media. pp. 217–92. doi:10.1007/978-3-0348-7068-9_5. ISBN 9783642661907. PMID 4982663. Retrieved 3 October 2017.
{{cite book}}
: |journal=
ignored (help)
|
---|
SSRIsTooltip Selective serotonin reuptake inhibitors | |
---|
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors | |
---|
NRIsTooltip Norepinephrine reuptake inhibitors | |
---|
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors | |
---|
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants | |
---|
SARIsTooltip Serotonin antagonist and reuptake inhibitors | |
---|
SMSTooltip Serotonin modulator and stimulators | |
---|
Others | |
---|
|
|
|
---|
TCAsTooltip Tricyclic antidepressants | |
---|
TeCAsTooltip Tetracyclic antidepressants | |
---|
Others | |
---|
|
|
|
---|
Non-selective | |
---|
MAOATooltip Monoamine oxidase A-selective | |
---|
MAOBTooltip Monoamine oxidase B-selective | |
---|
|
|
|
|
|
|
---|
Non-specific | AAADTooltip Aromatic L-amino acid decarboxylase | |
---|
MAOTooltip Monoamine oxidase | |
---|
|
---|
Phenethylamines (dopamine, epinephrine, norepinephrine) | PAHTooltip Phenylalanine hydroxylase | |
---|
THTooltip Tyrosine hydroxylase | - Substrates→Products: Tyrosine→L-DOPA (levodopa)
|
---|
DBHTooltip Dopamine beta-monooxygenase | |
---|
PNMTTooltip Phenylethanolamine N-methyltransferase | - Inhibitors: CGS-19281A
- SKF-64139
- SKF-7698
|
---|
COMTTooltip Catechol-O-methyl transferase | |
---|
|
---|
Tryptamines (serotonin, melatonin) | TPHTooltip Tryptophan hydroxylase | |
---|
AANATTooltip Serotonin N-acetyl transferase | |
---|
ASMTTooltip Acetylserotonin O-methyltransferase | |
---|
|
---|
Histamine | HDCTooltip Histidine decarboxylase | |
---|
HNMTTooltip Histamine N-methyltransferase | - Substrates→Products: Histamine→N-Methylhistamine
|
---|
DAOTooltip Diamine oxidase | - Substrates→Products: Histamine→Imidazole acetic acid
|
---|
|
---|
See also: Receptor/signaling modulators • Adrenergics • Dopaminergics • Melatonergics • Serotonergics • Monoamine reuptake inhibitors • Monoamine releasing agents • Monoamine neurotoxins |